Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Why the study?
Does aficamten reduce LVOT gradients and improve biomarkers and symptoms in patients with obstructive hypertrophic cardiomyopathy?
Population
Patients with obstructive hypertrophic cardiomyopathy
Comparison
Aficamten
Design
Phase 2 study
Authors
Discussion
Loading...
Member takes
Implication
May benefit symptomatic obstructive HCM; hypothesis-generating pending phase 3 confirmation.
Structured PICO
Does aficamten reduce LVOT gradients and improve biomarkers and symptoms in patients with obstructive hypertrophic cardiomyopathy?
P
Population
Patients with obstructive hypertrophic cardiomyopathy (oHCM)
I
Intervention
Aficamten
O
Outcome
LVOT gradients, biomarkers, and symptomssurrogate
Aficamten, a sarcomere-targeted therapy, effectively reduces LVOT gradients and improves symptoms in patients with obstructive hypertrophic cardiomyopathy.
Cite This Study
Maron et al. (2023) studied this question.